Comments
J&J close to settling with DOJ over marketing: WSJ
21.06.2012. | (Reuters) - Johnson & Johnson is close to reaching a settlement with the U.S. Justice Department over allegations it promoted anti psychotic drug Risperdal for unapproved uses that could cost the healthcare conglomerate at least $1.5 billion, the Wall Street Journal reported on Wednesday....
